Our study found that DNBs and four genes (SCD, NARS2, ALDH1A1, and NFXL1), as relevant factors associated with androgen-related signaling pathways in prostate cancer cells, can be further used as indicators of PCa progression after androgen deprivation therapy. This evidence concerns the gene NARS2 and prostate carcinoma.